Review



compounds having a gpr 40 receptor function modulating action  (Eli Lilly)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Eli Lilly compounds having a gpr 40 receptor function modulating action
    Compounds Having A Gpr 40 Receptor Function Modulating Action, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compounds+having+a+gpr+40+receptor+function+modulating+action/gpr40+agonists/us10246470-150-6-36
    Average 90 stars, based on 1 article reviews
    compounds having a gpr 40 receptor function modulating action - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: Heterocyclic compounds
    Article Snippet: No. 7,517,910 claims compounds having a GPR 40 receptor function modulating action, which are useful as insulin secretagogues, agents for the prophylaxis or treatment of diabetes and the like Novel Spiropiperidine compounds have been mentioned by Eli Lilly & Company in WO 2011066183 Eli Lilly also disclosed the following Spiropiperidines in patent application no. US20110092531 Novel 1,2,3,4-tetrahydroquinoline derivatives useful for the treatment of diabetes have been described by Eli Lilly & Company in patent application no. WO 2013025424 A patent application, WO 2013147443 titled “Preparation of β-substituted carboxylic acid derivatives for the treatment of diabetes” has been published by Daichi Sankyo.

    Article Title: Heterocyclic compounds
    Article Snippet: No. 7,517,910 claims compounds having a GPR 40 receptor function modulating action, which are useful as insulin secretagogues, agents for the prophylaxis or treatment of diabetes and the like Novel Spiropiperidine compounds have been mentioned by Eli Lilly & Company in WO 2011066183 Eli Lilly also disclosed the following Spiropiperidines in patent application no. US20110092531 Novel 1,2,3,4-tetrahydroqiunoline derivatives useful for the treatment of diabetes have been described by Eli Lilly & Company in patent application no. WO 2013025424 A patent application, WO 2013147443 titled “Preparation of β-substituted carboxylic acid derivatives for the treatment of diabetes” has been published by Daichi Sankyo.



    Similar Products

    90
    Eli Lilly compounds having a gpr 40 receptor function modulating action
    Compounds Having A Gpr 40 Receptor Function Modulating Action, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compounds+having+a+gpr+40+receptor+function+modulating+action/gpr40+agonists/us10246470-150-6-36
    Average 90 stars, based on 1 article reviews
    compounds having a gpr 40 receptor function modulating action - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    Image Search Results